Show filters
Resources type
Filter by Resources type
Pathologies
Filter by Pathologies
Technologies
Filter by Technologies
Instruments
Filter by Instruments
55 result(s) found
Sort by:

Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays

Press Release
Mar. 06, 2024

Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.

Methods for FLC quantification

Webinar
Feb. 29, 2024

Educational Workshop with Dr Matthias Orth

Complete your Myeloma diagnostic tools with Sebia FLC Assay

Brochure
Feb. 29, 2024

The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.

Multiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays

Publication
Feb. 29, 2024

The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.

How External Quality Assessment supports quality improvement in laboratory hemoglobinopathy diagnosis

Webinar
Feb. 19, 2024

Educational Workshop with Dr. Barbara De la Salle

HYDRASYS 2 SCAN FOCUSING: Overview

Video
Feb. 13, 2024

Learn more about the HYDRASYS 2 SCAN FOCUSING for a fast and user-friendly gel electrophoresis processing.

Sebia USA Learning Series

Webinar
Dec. 06, 2023

Sebia specializes in providing testing solutions for a range of diseases, including Diabetes and Multiple Myeloma. Learn about the impact of these diseases and the medical solutions available.